Quince Therapeutics, Inc.QNCXNASDAQ
Loading
SG&A Expenses Over TimeContracting
Percentile Rank38
3Y CAGR-15.6%
5Y CAGR-2.3%
Year-over-Year Change
Selling, general, and administrative expenses
3Y CAGR
-15.6%/yr
vs +89.1%/yr prior
5Y CAGR
-2.3%/yr
Recent deceleration
Acceleration
-104.7pp
Decelerating
Percentile
P38
Within normal range
vs 5Y Ago
0.9x
Contraction
Streak
4 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $15.64M | -11.0% |
| 2024 | $17.58M | -0.6% |
| 2023 | $17.70M | -32.0% |
| 2022 | $26.01M | -11.9% |
| 2021 | $29.52M | +67.9% |
| 2020 | $17.59M | +96.4% |
| 2019 | $8.95M | +340.2% |
| 2018 | $2.03M | +60.0% |
| 2017 | $1.27M | - |